Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series

Abstract

Egypt had been vexed by the highest load of chronic hepatitis C in the world. It represents a vast market of the new direct-acting anti-viral drugs (DAAs); effectively treating chronic hepatitis C virus (HCV) infection. Eradication of HCV in Egypt has been challenged by the observed increased diagnosis of hepatocellular carcinoma (HCC) in relation to DAAs therapy. This is the first Egyptian report annotating to a series of sixteen chronic HCV infected cases without a diagnosis of HCC before DAAs therapy and unexpected development of HCC during or after completion of DAAs therapy.

Keywords

Chronic hepatitis C / direct-acting anti-viral drugs / hepatocellular carcinoma / Egypt

References

[1] Goossens N.Hepatitis C virus-induced hepatocellular carcinoma..Clin Mol Hepatol2015;21:105-14 PMCID:PMC4493352

[2] de Oliveria Andrade LJ,Melo RC,Costa Silva CA.Association between hepatitis C and hepatocellular carcinoma..J Glob Infect Dis2009;1:33-7 PMCID:PMC2840947

[3] Reig M,Perelló C,Ribeiro A,Díaz A,Darnell A,Sangro B,Forns X.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[4] Conti F,Scuteri A,Bolondi L,Foschi FG,Mazzella G,Andreone P.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals..J Hepatol2016;65:727-33

[5] ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts).Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts..J Hepatol2016;65:734-40

[6] Innes H,Hayes P,Allen S,Mills PR,Wilks D,Fox R,Kennedy N,Fraser A,Bramley P.Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population..J Hepatol2017;66:19-27

[7] Bailly F,Virlogeux V.Antiviral therapy in patients with hepatitis C virus-induced cirrhosis..Dig Dis2015;33:613-23

[8] Kozbial K,Schwarzer R,Al-Zoairy R,Stättermayer AF,Graziadei I,Maieron A,Strasser M,Trauner M,Ferenci P.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment..J Hepatol2016;65:856-8

[9] Serti E,Keane M,Rivera E,Ghany M.Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN..Gut2017;66:724-35

[10] Meissner EG,Osinusi A,Qin J,McHutchison J,Sampson M,Patel K,Masur H.Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients..Hepatology2015;61:790-801 PMCID:PMC4340816

[11] van der Meer AJ,Feld JJ,Dufour JF,Duarte-Rojo A,Manns MP,Zeuzem S,de Knegt RJ,Janssen HL.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis..JAMA2012;308:2584-93

[12] Hsu CS,Lin HH,Kao JH.Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma..Sci Rep2015;5:9954 PMCID:PMC4428066

[13] Pasquali S.The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma..Curr Med Chem2010;17:3327-36

[14] Nelson MH.Novel immunotherapies for hematologic malignancies..Immunol Rev2015;263:90-105 PMCID:PMC4277117

[15] Zhao J,Li Z,Cai Y,Wang SH.Interferon-alpha-2b induces autophagy in hepatocellular carcinoma cells through Beclin1 pathway..Cancer Biol Med2014;11:64-8

[16] Sui X,Wang Z,Kong N,Han W,Yang J,Wang X,Pan H.Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment..Cell Death Dis2013;4:e838

[17] Liang KH,Chang ML,Lai MW.Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B..J Infect Dis2016;213:966-74

[18] Mandorfer M,Schwabl PH,Schwarzer R,Chromy D,Reiberger TH,Sieghart W,Hofer H,Ferenci P.Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension..J Hepatol2016;65:692-9